Eledon Pharmaceuticals, Inc. (ELDN)

Market Cap	116.48M
Revenue (ttm)	n/a
Net Income (ttm)	-82.67M
Shares Out	75.15M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,458,796
Open	1.680
Previous Close	1.670
Day's Range	1.540 - 1.685
52-Week Range	1.350 - 5.080
Beta	0.75
Analysts	Strong Buy
Price Target	11.00 (+609.68%)
Earnings Date	Nov 14, 2025

About ELDN

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 31
• Stock Exchange: NASDAQ
• Ticker Symbol: ELDN
• Website: https://eledon.com

Analyst Summary

According to 3 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price target is $11.0, which is an increase of 609.68% from the latest price.

Price Target

$11.0

(609.68% upside)

Analyst Consensus: Strong Buy